Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
155 hedge funds and large institutions have $1.48B invested in Aimmune Therapeutics in 2018 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 57 increasing their positions, 31 reducing their positions, and 17 closing their positions.
159% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 17
84% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 31
20% more funds holding
Funds holding: 129 → 155 (+26)
5% more capital invested
Capital invested by funds: $1.41B → $1.48B (+$65.1M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
16% less call options, than puts
Call options by funds: $24.1M | Put options by funds: $28.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$71.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$69.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.2M |
| 5 |
DM
Deerfield Management
New York
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$26.4M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$20.9M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$20.8M |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$16.5M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.9M |
AIMT Hedge Fund Activity: Q1 2018 in Review
155 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2018, worth a combined $1.48B — up 4.6% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new AIMT positions and 17 closed out — a net gain of 27 holders — while 57 added to existing stakes and 31 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $71.1M. The largest seller was Adage Capital Partners, cutting an estimated $26.4M.
- 155 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2018, up from 129 in Q4 2017.
- Funds reported $1.48B of Aimmune Therapeutics stock for Q1 2018, up 4.6% quarter-over-quarter.
- 44 funds opened new Aimmune Therapeutics positions in Q1 2018 and 17 closed out, a net change of +27 holders.
- The largest Aimmune Therapeutics buyer in Q1 2018 was Wellington Management Group, an estimated $71.1M added.
- The largest Aimmune Therapeutics seller in Q1 2018 was Adage Capital Partners, an estimated $26.4M sold.
Based on aggregated 13F filings for Q1 2018.